Prp gel compound and preparation method thereof

Abstract

The present invention belongs to the field of gel complexes, and provides a prp gel complex and a preparation method thereof, the prp gel complex comprises a platelet concentrate (PRP), a biocompatible polymer matrix, a cross-linking agent and at least one regulator, the platelet concentrate is uniformly dispersed in the biocompatible polymer matrix, and the cross-linking agent is a cross-linking agent. A stable gel network structure is formed through the cross-linking agent; according to the PRP gel compound and the preparation method thereof provided by the invention, the composition and proportion of the PRP, the biocompatible polymer matrix, the cross-linking agent and the regulator are accurately regulated and controlled, and a series of innovative algorithms are utilized to optimize the preparation process, so that the problems that the traditional gel compound is single in component and limited in performance regulation are effectively solved; precise regulation and control of the performance of the gel compound and efficient preparation are achieved, and a novel biological material which is excellent in performance and wide in application is provided for the fields of biomedical engineering and material science.

Description

Technical Field

[0001] The invention belongs to the field of gel composites, in particular to a prp gel composite and a preparation method thereof. Background Art

[0002] In the field of biomedical engineering and materials science, the development of efficient and controllable biomaterials has always been a research hotspot. Although traditional gel composites have shown certain potential in tissue repair and drug carriers, their single composition and limited performance adjustment make it difficult to meet the diverse needs under complex physiological environments. In particular, platelet concentrate (PRP), as a valuable resource in the blood, is rich in a variety of growth factors and cytokines, and has a significant effect on promoting cell proliferation, differentiation and tissue repair. However, how to effectively and stably integrate PRP into gel composites while ensuring that the gel has good biocompatibility, adjustable mechanical properties and biological activity is a challenge facing current technology.

[0003] The gel complexes in the prior art often lack a systematic method to achieve uniform dispersion and stable existence of PRP, resulting in the inability to fully exert the biological activity of PRP and the difficulty in accurately regulating the performance of the gel according to specific needs. In addition, the preparation process of the gel often relies on empirical judgment and lacks scientific and quantitative guidance, resulting in large differences in the quality and performance of the prepared gel complexes.

[0004] To this end, those skilled in the art have proposed a prp gel complex and a preparation method thereof to solve the problems raised in the background art. Summary of the invention

[0005] In order to solve the above technical problems, the present invention provides a prp gel composite and a preparation method thereof to solve the problems existing in the prior art.

[0006] A prp gel complex and a preparation method thereof, comprising platelet concentrate (PRP), a biocompatible polymer matrix, a cross-linking agent and at least one regulator, wherein the platelet concentrate is uniformly dispersed in the biocompatible polymer matrix and forms a stable gel network structure through the cross-linking agent.

[0007] Preferably, the platelet concentrate is a platelet-rich plasma fraction obtained by centrifuging whole blood, wherein the optimal centrifugation conditions are determined using Algorithm B, where Algorithm B is: Where RCF is the relative centrifugal force, ω is the centrifugal angular velocity, r is the centrifugal radius, and g is the gravitational acceleration.

[0008] Preferably, the biocompatible polymer matrix is ​​selected from but not limited to one or more combinations of polylactic acid-co-glycolide (PLGA), hyaluronic acid, collagen or sodium alginate, and the molecular weight of the polymer matrix is ​​determined by algorithm C, which is Mw=k'×Vp / Cp, where Mw is the desired polymer molecular weight, k' is a constant determined according to the polymer type, Vp is the volume of the polymer solution, and Cp is the polymer concentration.

[0009] Preferably, the crosslinking agent is a chemical crosslinking agent or a physical crosslinking agent, and the chemical crosslinking agent includes but is not limited to genipin, glutaraldehyde or carbodiimide compounds; the physical crosslinking agent includes but is not limited to ionic crosslinking or ultraviolet crosslinking, and the amount of the crosslinking agent used is determined by algorithm D, specifically Cused = (F×Mw) / (E×V), where Cused is the required crosslinking agent concentration), F is the target crosslinking degree, Mw is the polymer molecular weight, E is the crosslinking agent efficiency, and V is the volume of the polymer solution.

[0010] Preferably, the regulator is selected from but not limited to pH regulators, enzyme inhibitors or antioxidants, and its addition amount is determined by algorithm E: Dadd = (P×Vg) / (S×We), wherein Dadd is the required amount of regulator added, P is the target performance parameter, such as degradation rate, mechanical strength, etc., Vg is the gel volume, S is the regulator sensitivity coefficient, and We is the effective concentration of the regulator.

[0011] Preferably, the preparation of the PRP gel complex also includes adding at least one bioactive factor, wherein the bioactive factor is selected from one or more of growth factors, cytokines or drugs, and the amount added is determined by algorithm F, specifically Bf=(T×Vg) / (Ef×Wbf), wherein Bf is the required amount of bioactive factor added, T is the target therapeutic effect, Vg is the gel volume, Ef is the bioactive factor efficiency, and Wbf is the bioactive factor concentration.

[0012] A method for preparing a prp gel complex, for manufacturing the above-mentioned prp gel complex, comprises the following steps, S1: collecting a whole blood sample and centrifuging it to separate platelet concentrate (PRP), wherein the centrifugation conditions are determined according to algorithm B;

[0013] S2: mixing the platelet concentrate with a biocompatible polymer matrix to form a mixture, wherein the molecular weight of the polymer matrix is ​​determined according to Algorithm C;

[0014] S3: adding a predetermined amount of a cross-linking agent to the mixture and stirring the mixture uniformly, wherein the amount of the cross-linking agent used is determined according to Algorithm D;

[0015] S4: Apply algorithm A to calculate the required crosslinking time t, where algorithm A is t = k × V 0.5 / C, where k is a constant (0.01-0.1), V is the volume of the mixture, and C is the crosslinker concentration;

[0016] S5: performing cross-linking treatment on the mixture within the calculated cross-linking time t to form a gel precursor;

[0017] S6: subjecting the gel precursor to a molding process to obtain the PRP gel complex, and adding a regulator, wherein the amount of the regulator added is determined according to Algorithm E.

[0018] Preferably, in step S2, the biocompatible polymer matrix needs to be dissolved in a suitable solvent before being added to form a polymer solution, and the solvent type and concentration are determined by algorithm G during the preparation of the polymer solution. Algorithm G is Stype=min(ΔH×Cp / ΔT), where Stype is the optimal solvent type, ΔH is the dissolution enthalpy, Cp is the specific heat capacity of the polymer solution, and ΔT is the dissolution temperature difference.

[0019] Preferably, the algorithm A in step S4 further includes adjusting the value of the constant k according to the target gel strength, wherein the target gel strength is proportional to the k value, and the target gel strength is determined by an algorithm H, the algorithm H is σ=k"×(1-ε), wherein σ is the target gel strength, k" is a constant determined according to the polymer type and the crosslinker type, and ε is the porosity of the gel.

[0020] Preferably, after step S6, the method further comprises step S7: performing post-treatment on the PRP gel complex, including washing, drying and / or sterilization, and applying algorithm I to determine the optimal sterilization conditions during the sterilization process, where algorithm I is Tster=(D×log 10 (NO / NC)) / Z, where Tster is the required sterilization time, D is the sterilization value, that is, the time required to reduce 10^6 microorganisms, No is the initial number of microorganisms, Nc is the number of microorganisms allowed after sterilization, and Z is the temperature coefficient.

[0021] Through the above technical solution,

[0022] Compared with the prior art, the present invention has the following beneficial effects:

[0023] 1. The PRP gel complex and its preparation method provided by the present invention effectively solve the problems of single component and limited performance adjustment of traditional gel complexes by precisely controlling the composition and ratio of platelet concentrate (PRP), biocompatible polymer matrix, cross-linking agent and regulator, and optimizing the preparation process by using a series of innovative algorithms, thereby achieving precise control and efficient preparation of the performance of the gel complex, and providing a new type of biomaterial with excellent performance and wide application for the fields of biomedical engineering and materials science. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 It is a flowchart of the steps of the preparation method in the present invention; DETAILED DESCRIPTION

[0025] The following embodiments of the present invention are described in further detail in conjunction with the accompanying drawings and examples. The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention.

[0026] Embodiment 1: The present invention provides a prp gel complex, including platelet concentrate (PRP), a biocompatible polymer matrix, a cross-linking agent and at least one regulator, wherein the platelet concentrate is uniformly dispersed in the biocompatible polymer matrix, and a stable gel network structure is formed through the cross-linking agent, and a significant improvement in performance is achieved by integrating multiple key components. Platelet concentrate is rich in growth factors and cytokines, which helps to promote tissue repair and regeneration; the biocompatible polymer matrix provides a stable structural support for the gel; the cross-linking agent ensures the stability and durability of the gel network; the regulator is used to adjust the degradation rate, mechanical strength and other properties of the gel to meet different application requirements. By accurately controlling the proportion and distribution of each component, it can be ensured that the gel complex has excellent biocompatibility, stability and controllability, providing a solid foundation for the optimization and application of subsequent steps.

[0027] Furthermore, the platelet concentrate is a platelet-rich plasma fraction obtained by centrifuging whole blood, and the optimal centrifugation conditions are determined by applying algorithm B during the centrifugation process. Algorithm B is: Where RCF is the relative centrifugal force, ω is the centrifugal angular velocity, r is the centrifugal radius, and g is the gravitational acceleration. The algorithm is used to determine the optimal centrifugal conditions to ensure that high-quality platelet concentrate can be obtained in each centrifugation. This not only improves the preparation efficiency, but also ensures the performance consistency of the gel complex, ensures the quality and stability of the platelet concentrate in the PRP gel complex, and provides a reliable guarantee for mixing and cross-linking with other components in subsequent steps.

[0028] Preferably, the biocompatible polymer matrix is ​​selected from, but not limited to, one or more combinations of polylactic acid-co-glycolide (PLGA), hyaluronic acid, collagen or sodium alginate, and the molecular weight of the polymer matrix is ​​determined by algorithm C, which is Mw=k'×Vp / Cp, where Mw is the desired polymer molecular weight, k' is a constant determined according to the polymer type, Vp is the polymer solution volume, and Cp is the polymer concentration. The optimal polymer molecular weight is determined by algorithm C, which can ensure the compatibility of the polymer matrix with the platelet concentrate and other components while meeting specific performance requirements. This precise control helps to improve the overall performance and stability of the gel complex.

[0029] As can be seen from the above, the present invention summarizes the basic composition of the prp gel complex, including platelet concentrate (PRP), a biocompatible polymer matrix, a cross-linking agent and a regulator, to form a stable gel network structure, and at the same time describes in detail the method for obtaining platelet concentrate (PRP), that is, obtaining the platelet-rich plasma portion by centrifuging whole blood and using a specific algorithm B to determine the optimal centrifugation conditions, and through the selection of the biocompatible polymer matrix and the determination of its molecular weight, the polymer matrix can be selected from a variety of materials such as polylactic acid-co-glycolide (PLGA), hyaluronic acid, and the required polymer molecular weight is determined by algorithm C.

[0030] Embodiment 2: This embodiment is basically the same as the previous embodiment, except that the crosslinking agent is a chemical crosslinking agent or a physical crosslinking agent, and the chemical crosslinking agent includes but is not limited to genipin, glutaraldehyde or carbodiimide compounds; the physical crosslinking agent includes but is not limited to ionic crosslinking or ultraviolet crosslinking, and the amount of the crosslinking agent used is determined by algorithm D, specifically Cused = (F × Mw) / (E × V), where Cused is the required crosslinking agent concentration), F is the target crosslinking degree, Mw is the polymer molecular weight, E is the crosslinking agent efficiency, V is the volume of the polymer solution, the crosslinking agent is a chemical crosslinking agent or a physical crosslinking agent, and the amount of the crosslinking agent used is determined by algorithm D. The use of algorithm D to determine the optimal type and amount of the crosslinking agent can ensure the stability and durability of the gel network structure. This precise control helps to improve the mechanical strength and biocompatibility of the gel composite, ensures the precise control of the type and amount of the crosslinking agent, and provides an important guarantee for the stability and durability of the gel network structure.

[0031] Preferably, the regulator is selected from but not limited to pH regulators, enzyme inhibitors or antioxidants, and its addition amount is determined by algorithm E: Dadd = (P×Vg) / (S×We), where Dadd is the required amount of regulator, P is the target performance parameter, such as degradation rate, mechanical strength, etc., Vg is the gel volume, S is the regulator sensitivity coefficient, and We is the effective concentration of the regulator. The algorithm E is used to determine the best regulator type and addition amount, which can accurately adjust the degradation rate, mechanical strength and other properties of the gel to meet different application requirements. This precise control helps to improve the adaptability and application range of the gel composite, ensures the precise control of the regulator type and addition amount, and provides an important means for the performance adjustment of the gel composite.

[0032] Furthermore, the preparation of the PRP gel complex also includes adding at least one bioactive factor, the bioactive factor is selected from one or more of growth factors, cytokines or drugs, and the amount of addition is determined by algorithm F, specifically Bf = (T × Vg) / (Ef × Wbf), where Bf is the required amount of bioactive factor added, T is the target treatment effect, Vg is the gel volume, Ef is the efficiency of the bioactive factor, and Wbf is the concentration of the bioactive factor. The algorithm F is used to determine the optimal type and amount of bioactive factor, which can significantly improve the bioactivity of the gel complex and promote tissue repair and regeneration. This precise control helps to enhance the therapeutic effect and application value of the gel complex, and provides an important guarantee for the bioactivity and therapeutic effect of the gel complex.

[0033] Embodiment 3: As shown in the attached Figure 1 As shown: Based on Example 1, the present invention provides a method for preparing a prp gel complex, which is used to manufacture the above-mentioned gel complex, comprising the following steps: S1: collecting a whole blood sample and centrifuging it to separate platelet concentrate (PRP), and the centrifugation conditions are determined according to algorithm B;

[0034] S2: mixing the platelet concentrate with a biocompatible polymer matrix to form a mixture, wherein the molecular weight of the polymer matrix is ​​determined according to Algorithm C;

[0035] S3: adding a predetermined amount of a cross-linking agent to the mixture and stirring the mixture uniformly, wherein the amount of the cross-linking agent used is determined according to Algorithm D;

[0036] S4: Apply algorithm A to calculate the required crosslinking time t, where algorithm A is t = k × V 0.5 / C, where k is a constant (0.01-0.1), V is the volume of the mixture, and C is the crosslinker concentration;

[0037] S5: performing cross-linking treatment on the mixture within the calculated cross-linking time t to form a gel precursor;

[0038] S6: subjecting the gel precursor to a molding process to obtain the PRP gel complex, and adding a regulator, wherein the amount of the regulator added is determined according to Algorithm E.

[0039] Further, in step S2, the biocompatible polymer matrix needs to be dissolved in a suitable solvent before being added to form a polymer solution, and the solvent type and concentration are determined by algorithm G during the preparation of the polymer solution. Algorithm G is Stype=min(ΔH×Cp / ΔT), where Stype is the optimal solvent type, ΔH is the dissolution enthalpy, Cp is the specific heat capacity of the polymer solution, and ΔT is the dissolution temperature difference. The present invention uses algorithm G to determine the optimal solvent type and concentration, which can ensure the complete dissolution and stable dispersion of the polymer matrix in the solvent. This helps to improve the uniformity and stability of the gel complex, ensures the complete dissolution and stable dispersion of the biocompatible polymer matrix in the solvent, and provides a reliable guarantee for the subsequent mixing and cross-linking steps.

[0040] Preferably, the algorithm A in step S4 further includes adjusting the value of the constant k according to the target gel strength, wherein the target gel strength is proportional to the k value, and the target gel strength is determined by the algorithm H, the algorithm H is σ=k"×(1-ε), wherein σ is the target gel strength, k" is a constant determined according to the polymer type and the crosslinking agent type, ε is the porosity of the gel, and the algorithm A is used to calculate the required crosslinking time, and the value of the constant k is adjusted according to the target gel strength, which can ensure the stability and durability of the gel network structure. This precise control helps to improve the mechanical strength and biocompatibility of the gel composite, ensures the accurate calculation of the crosslinking time and the stability of the gel network structure, and provides an important guarantee for the performance of the gel composite.

[0041] Furthermore, after step S6, the method further comprises step S7: performing post-treatment on the PRP gel complex, including washing, drying and / or sterilization, and applying algorithm I to determine the optimal sterilization conditions during the sterilization process, where algorithm I is Tster=(D×log 10 (NO / NC)) / Z, where Tster is the required sterilization time, D is the sterilization value, i.e., the time required to reduce 10^6 microorganisms, No is the initial number of microorganisms, Nc is the number of microorganisms allowed after sterilization, and Z is the temperature coefficient. The present invention uses algorithm I to determine the optimal sterilization conditions, which can ensure the safety and stability of the prp gel compound during the sterilization process. This precise control helps to extend the shelf life of the gel compound and reduce the risk of use, ensure the safety and stability of the prp gel compound during the post-processing process, and provide reliable protection for subsequent applications.

[0042] As can be seen from the above, the present invention includes collecting a whole blood sample and separating platelet concentrate (PRP) under centrifugal conditions determined by algorithm B, mixing it with a biocompatible polymer matrix with a molecular weight determined by algorithm C, adding a cross-linking agent in an amount determined by algorithm D and stirring, performing a cross-linking treatment after calculating the cross-linking time by algorithm A to form a gel precursor, and then reshaping and adding a regulator in an amount determined by algorithm E to obtain a prp gel complex; at the same time, it is proposed that algorithm G should be used to determine the solvent type and concentration when the polymer matrix is ​​dissolved, and the use of algorithm A includes adjusting the value of the constant k according to the target gel strength.

[0043] The embodiments of the present invention are provided for the purpose of illustration and description. Although the embodiments of the present invention have been shown and described above, it can be understood that the above embodiments are exemplary and cannot be understood as limitations of the present invention. Ordinary technicians in this field can change, modify, replace and modify the above embodiments within the scope of the present invention.

[0044] In the description of the present invention, the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include one or more of the features. "Multiple" means two or more, unless otherwise clearly and specifically defined.

[0045] In the present invention, unless otherwise clearly specified and limited, the terms "installed", "connected", "connected", "fixed" and the like should be understood in a broad sense, for example, it can be a fixed connection, a detachable connection, or an integral connection; it can be a mechanical connection or an electrical connection; it can be a direct connection or an indirect connection through an intermediate medium, it can be the internal connection of two elements or the interaction relationship between two elements. For ordinary technicians in this field, the specific meanings of the above terms in the present invention can be understood according to specific circumstances.

[0046] In the present invention, unless otherwise clearly specified and limited, a first feature being "above" or "below" a second feature may mean that the first and second features are in direct contact, or the first and second features are in indirect contact through an intermediate medium. Moreover, a first feature being "above", "above" or "above" a second feature may mean that the first feature is directly above or obliquely above the second feature, or simply means that the first feature is higher in level than the second feature. A first feature being "below", "below" or "below" a second feature may mean that the first feature is directly below or obliquely below the second feature, or simply means that the first feature is lower in level than the second feature.

[0047] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "examples", "specific examples" or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine different embodiments or examples described in this specification and the features of different embodiments or examples, unless they are contradictory.

[0048] In the drawings of the embodiments disclosed in the present invention, only the structures involved in the embodiments disclosed in the present invention are involved, and other structures can refer to the general design. In the absence of conflict, the same embodiment and different embodiments of the present invention can be combined with each other.

[0049] Although the present invention has been described in detail with reference to the aforementioned embodiments, it is still possible for those skilled in the art to modify the technical solutions described in the aforementioned embodiments, or to make equivalent substitutions for some of the technical features therein. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A prp gel complex, characterized in that: The invention comprises platelet concentrate (PRP), a biocompatible polymer matrix, a cross-linking agent and at least one regulator. The platelet concentrate is uniformly dispersed in the biocompatible polymer matrix and forms a stable gel network structure through the cross-linking agent.

2. A prp gel complex as claimed in claim 1, characterized in that: The platelet concentrate is the platelet-rich plasma fraction obtained by centrifuging whole blood. During the centrifugation process, algorithm B is used to determine the optimal centrifugation conditions. Algorithm B is: Where RCF is the relative centrifugal force, ω is the centrifugal angular velocity, r is the centrifugal radius, and g is the gravitational acceleration.

3. A prp gel complex as claimed in claim 2, characterized in that: The biocompatible polymer matrix is ​​selected from but not limited to one or more combinations of polylactic acid-co-glycolide (PLGA), hyaluronic acid, collagen or sodium alginate, and the molecular weight of the polymer matrix is ​​determined by algorithm C, which is Mw=k'×Vp / Cp, where Mw is the desired polymer molecular weight, k' is a constant determined according to the polymer type, Vp is the volume of the polymer solution, and Cp is the polymer concentration.

4. A prp gel complex as claimed in claim 3, characterized in that: The cross-linking agent is a chemical cross-linking agent or a physical cross-linking agent, and the chemical cross-linking agent includes but is not limited to genipin, glutaraldehyde or carbodiimide compounds; the physical cross-linking agent includes but is not limited to ionic cross-linking or ultraviolet cross-linking, and the amount of the cross-linking agent used is determined by algorithm D, specifically Cused=(F×Mw) / (E×V), where Cused is the required cross-linking agent concentration), F is the target cross-linking degree, Mw is the polymer molecular weight, E is the cross-linking agent efficiency, and V is the volume of the polymer solution.

5. A prp gel complex as claimed in claim 4, characterized in that: The regulator is selected from but not limited to pH regulators, enzyme inhibitors or antioxidants, and its addition amount is determined by algorithm E: Dadd = (P×Vg) / (S×We), wherein Dadd is the required amount of regulator added, P is the target performance parameter, such as degradation rate, mechanical strength, etc., Vg is the gel volume, S is the regulator sensitivity coefficient, and We is the effective concentration of the regulator.

6. A prp gel complex as claimed in claim 5, characterized in that: The preparation of the PRP gel complex also includes adding at least one bioactive factor, wherein the bioactive factor is selected from one or more of growth factors, cytokines or drugs, and the amount of addition is determined by algorithm F, specifically Bf=(T×Vg) / (Ef×Wbf), wherein Bf is the required amount of bioactive factor added, T is the target treatment effect, Vg is the gel volume, Ef is the bioactive factor efficiency, and Wbf is the bioactive factor concentration.

7. A method for preparing a prp gel composite, used for manufacturing the gel composite according to claims 1-6, characterized in that: The method comprises the following steps: S1: collecting a whole blood sample and centrifuging it to separate platelet concentrate (PRP), wherein the centrifugation conditions are determined according to algorithm B; S2: mixing the platelet concentrate with a biocompatible polymer matrix to form a mixture, wherein the molecular weight of the polymer matrix is ​​determined according to Algorithm C; S3: adding a predetermined amount of a cross-linking agent to the mixture and stirring the mixture uniformly, wherein the amount of the cross-linking agent used is determined according to Algorithm D; S4: Apply algorithm A to calculate the required crosslinking time t, where algorithm A is t = k × V 0.5 / C, where k is a constant (0.01-0.1), V is the volume of the mixture, and C is the crosslinker concentration; S5: performing cross-linking treatment on the mixture within the calculated cross-linking time t to form a gel precursor; S6: subjecting the gel precursor to a molding process to obtain the PRP gel complex, and adding a regulator, wherein the amount of the regulator added is determined according to Algorithm E.

8. A prp gel complex and a preparation method thereof as claimed in claim 7, characterized in that: In step S2, the biocompatible polymer matrix needs to be dissolved in a suitable solvent before being added to form a polymer solution, and the solvent type and concentration are determined by algorithm G during the preparation of the polymer solution. Algorithm G is Stype=min(ΔH×Cp / ΔT), where Stype is the optimal solvent type, ΔH is the dissolution enthalpy, Cp is the specific heat capacity of the polymer solution, and ΔT is the dissolution temperature difference.

9. A prp gel complex and a preparation method thereof as claimed in claim 7, characterized in that: The algorithm A in step S4 further includes adjusting the value of the constant k according to the target gel strength, wherein the target gel strength is proportional to the k value, and the target gel strength is determined by the algorithm H, the algorithm H is σ=k"×(1-ε), wherein σ is the target gel strength, k" is a constant determined according to the polymer type and the cross-linking agent type, and ε is the porosity of the gel.

10. A prp gel complex and a preparation method thereof as claimed in claim 7, characterized in that: After step S6, the method further includes step S7: performing post-treatment on the PRP gel complex, including washing, drying and / or sterilization, and applying algorithm I to determine the optimal sterilization conditions during the sterilization process, where algorithm I is Tster=(D×log 10 (NO / NC)) / Z, where Tster is the required sterilization time, D is the sterilization value, that is, the time required to reduce 10^6 microorganisms, No is the initial number of microorganisms, Nc is the number of microorganisms allowed after sterilization, and Z is the temperature coefficient.

Images